TheraGuide 5-FU™ is the most comprehensive clinically available test for assessing the risk of toxicity due to 5-FU–based chemotherapy.
-
Although adverse reactions to therapy are often manageable, they can result in the following:
- A reduction in chemotherapy dosing
- Delays in treatment
- Changes or discontinuation of chemotherapy
- Extra medical attention to address harmful side effects
- Patient discomfort and diminished quality of life
- Hospitalization
- The potential for these complications may affect the timing and effectiveness of the patient's treatment
- Rapid turnaround of test results allows you to know if your patient is at high risk before starting chemotherapy, which means you can personalize therapy
Now you can better manage patients who are at increased toxicity risk
Options for reducing the risk of toxicity to 5-FU-based chemotherapy are available and should be considered when developing a patient management plan.
- Patients with certain DPYD or TYMS variants have up to a 60% risk of toxicity and may be appropriate for effective alternate chemotherapeutic agents
- Patients at high risk of toxicity may be appropriate for enhanced patient monitoring and dosage-reduction strategies where appropriate to limit the incidence and severity of adverse reactions
